AEGEA Medical develops the patented Adaptive Vapor Ablation technology and the AEGEA Vapor System, an FDA‑approved, office‑based endometrial ablation device that uses water vapor to treat menorrhagia. The system is designed to deliver a safe, quick, minimally invasive procedure in a doctor’s office. AEGEA positions the technology as a potential new standard of care for treating heavy menstrual bleeding and to preserve uterine cavity access after ablation. The company plans to commercialize a next‑generation Adaptive Vapor Ablation system in 2019. AEGEA is using recent financing to fund a prospective, multicenter Post‑Ablation Cavity Access (PACE II) study to evaluate uterine cavity access and the feasibility of minimally invasive interventions three to four years post‑ablation. Founded in 2008 and headquartered in Menlo Park, Calif., AEGEA is privately held. AEGEA Medical develops the Adaptive Vapor Ablation system, an FDA‑approved water vapor endometrial ablation technology for treating menorrhagia. The system is designed for office‑based procedures with minimal anesthesia/analgesia and rapid recovery, intended to expand access to appropriate patients. AEGEA is preparing for a commercial U.S. launch of the technology. The company closed a $40 million financing—$30 million led by Perceptive Advisors plus $10 million from existing equity investors—to fund operations during launch preparations. Named existing investors include Alloy Ventures, Delphi Ventures, Medtronic, BioMed Ventures, and Solas BioVentures. AEGEA was founded in 2008 and is based in Redwood City, California. Aegea Medical is a Redwood City, California–based medical device company founded in 2008 and led by CEO Don Gurskis. The company is developing the AEGEA Vapor System, a proprietary convective water vapor technology that delivers controlled, low-pressure natural water vapor to the uterine cavity to ablate the endometrium. The system is designed to deliver adaptive water vapor in an office-based, minutes-long procedure intended to reduce or stop uterine bleeding and improve quality of life for patients with menorrhagia. Aegea closed a $36m Series C financing to support regulatory advancement. The company intends to use the funds to complete its PMA submission and seek FDA approval to market its endometrial ablation procedure. AEGEA Medical is a clinical-stage medical device company developing a novel, minimally invasive global endometrial ablation system that uses vapor to rapidly ablate the uterine lining. The vapor is intended to conform to virtually any anatomy to provide complete ablation, and the procedure is designed to be performed by a gynecologist in an office setting. The company reports positive clinical results to date and plans to complete product development and begin the next stage of clinical testing using the newly raised capital. AEGEA completed a $13.3 million private equity financing led by Covidien Ventures, with Alloy Ventures and Delphi Ventures participating. Amy Belt, Director of Covidien Ventures, has joined AEGEA’s Board of Directors. The company is based in Redwood City, Calif., its products are not yet available for sale in the United States, and it targets a large market—abnormal uterine bleeding affects one in four women of reproductive age with about 2.5 million new U.S. patients seeking treatment annually.

Total raised

$106M

Funding rounds

4

Latest round

Equity

Latest activity

Nov 2018